Simcere Pharmaceutical Co., Ltd

Quick facts

Marketed products

• Gemcitabine-Cisplatin chemotherapy · Oncology
  Gemcitabine and cisplatin work synergistically to damage cancer cell DNA and prevent its repair, leading to cell death.

Phase 3 pipeline

• Edaravone Dexborneol Sequential Therapy · Neurology
  Edaravone reduces oxidative stress and neuroinflammation while dexborneol enhances cerebral blood flow and neuroprotection in a sequential combination therapy.
• SIM0718 Injection · Virology / Immunology
  SIM0718 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.
• SIM0916
  SIM0916 is a small molecule inhibitor that targets a specific molecular pathway involved in disease pathogenesis, though the exact mechanism requires further clarification.

Phase 2 pipeline

• Edaravone dexborneol sublingual tablet

Phase 1 pipeline

• cisplatin-fluorouracil chemotherapy
• Y-2 Sublingual Tablet

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Simcere Pharmaceutical Co., Ltd portfolio CI brief
• Simcere Pharmaceutical Co., Ltd pipeline updates RSS